We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Pharmaceutical company Mylan N.V. (MYL) on Friday announced the commercial launch of Hulio, a biosimilar to AbbVie's Humira, across major markets in Europe.
The company said the product is approved for all adalimumab indications and will be available to patients as soon as possible.
The European Commission approved Hulio in September 2018, following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use. The EC approval of Hulio applies to all 28 European Union member countries and European Economic Area member states of Norway, Iceland and Liechtenstein, the company said.
Hulio is indicated for the same indications of Humira, including rheumatoid arthritis, psoriatic arthritis, psoriasis and Crohn's disease in adults and plaque psoriasis and Crohn's disease in children.
Humira is the world's best-selling biologic medication.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 19, 2018 13:26 ET (17:26 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
